Prof. R. Scott Wright (Mayo Clinic, Rochester, USA) presented the latest data from the phase 3, randomised, placebo-controlled, double-blinded ORION-10 trial, testing the effect of the small interfering RNA (siRNA) inclisiran in patients with atherosclerotic cardiovascular disease (ASCVD) and elevated low-density lipoprotein cholesterol (LDL-C) . With a follow-up of 18 months, inclisiran halved LDL-C levels compared with placebo. The safety profile was favourable.
ORION-10 randomised 1,561 ASCVD patients with elevated LDL-C (≥70 mg/mL) who were already taking maximum tolerated statins to receive either 4 injections (at 0, 3, 9, and 15 months) of placebo or of 300 mg inclisiran with a follow-up of 18 months. The co-primary endpoints were percentage of LDL-C change from baseline at day 510 and the average percentage change from day 90 to day 540.
At the study end at day 510, LDL-C was 58...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Testosterone gel increases left ventricular mass Next Article
Intra-aortic balloon pump better than Impella: new observational data »
Table of Contents: AHA 2019
New Approaches to CVD Risk Reduction
Interventional Management for Acute Coronary Syndrome
Results for the Ischemia Trials: To Intervene or Not to Intervene
Controversies in Contemporary Management of Aortic Stenosis
Guidelines: Updates and Controversies
Trials in Electrophysiology and Left Ventricular Function
New Frontiers in Lipid Therapy
Challenges in Heart Failure Management
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.